Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21314303 | 0.83 | PPARG (0.41) | DPP4DPP8DPP9PPARGPPARA | |
| SCHEMBL21314307 | 0.83 | PPARG (0.41) | DPP4DPP8DPP9PPARGPPARA | |
| SCHEMBL21243716 | 0.80 | EPHX1 (0.52) | — | |
| SCHEMBL21243718 | 0.80 | EPHX1 (0.52) | — | |
| SCHEMBL4350725 | 0.78 | DPP4 (0.42) | DPP4DPP7DPP8DPP9ALDH1A1 | |
| SCHEMBL4350733 | 0.78 | DPP4 (0.42) | DPP4DPP7DPP8DPP9ALDH1A1 | |
| Carbamic Acid SCHEMBL28108559 | 0.77 | DPP4 (0.48) | DPP4DPP7DPP8DPP9ALDH1A1 | |
| SCHEMBL978947 | 0.77 | DPP4 (0.57) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL978945 | 0.77 | DPP4 (0.57) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL288309 | 0.77 | DPP4 (0.57) | DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110792-B1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2019-09-04 | — | — | EP | claimed |
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS., LTD. | 2021-04-22 | — | — | US | disclosed |
| US-10888542-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-01-12 | — | — | US | disclosed |
| US-20200046674-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
| EP-3110792-B1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2019-09-04 | — | — | EP | disclosed |
| US-20190247356-A1 | Aminocarbonylcarbamate Compounds | SK BIOPHARMACEUTICALS CO., LTD. | 2019-08-15 | — | — | US | disclosed |
| US-10314808-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-06-11 | — | — | US | disclosed |
| US-20180085337-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
| US-9833432-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| EP-3110792-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK Biopharmaceuticals Co., Ltd. (KR) | 2017-01-04 | — | — | EP | disclosed |
| US-20160303067-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. | 2016-10-20 | — | — | US | disclosed |
| US-9403761-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-08-02 | — | — | US | disclosed |
| US-20160168567-A1 | UNA SINGLE STRANDED OLIGOMERS FOR THERAPEUTICS | MARINA BIOTECH, INC. | 2016-06-16 | — | — | US | disclosed |
| WO-2015130121-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | WO | disclosed |
| US-20150246874-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247356-A1 | Aminocarbonylcarbamate Compounds | SLC6A3, SLC6A2, SLC6A4 | DPP4 1476/4885DPP7 1837/4885DPP8 2599/4885 |
| US-20150246874-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | DPP4 1476/4885DPP7 1837/4885DPP8 2599/4885 |
| US-10888542-B2 | Aminocarbonylcarbamate compounds | SLC6A3, SLC6A2, SLC6A4 | DPP4 1476/4885DPP7 1837/4885DPP8 2599/4885 |
| US-20160303067-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | DPP4 1476/4885DPP7 1837/4885DPP8 2599/4885 |
| US-20180085337-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | DPP4 1476/4885DPP7 1837/4885DPP8 2599/4885 |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | DPP4 1476/4885DPP7 1837/4885DPP8 2599/4885 |
| US-20200046674-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | DPP4 1476/4885DPP7 1837/4885DPP8 2599/4885 |
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | DPP4 1476/4885DPP7 1837/4885DPP8 2599/4885 |
| US-10314808-B2 | Aminocarbonylcarbamate compounds | SLC6A3, SLC6A2, SLC6A4 | DPP4 1476/4885DPP7 1837/4885DPP8 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.